We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia.
- Authors
Olupot-Olupot, Peter; Engoru, Charles; Thompson, Jennifer; Nteziyaremye, Julius; Chebet, Martin; Ssenyondo, Tonny; Dambisya, Cornelius M; Okuuny, Vicent; Wokulira, Ronald; Amorut, Denis; Ongodia, Paul; Mpoya, Ayub; Williams, Thomas N; Uyoga, Sophie; Macharia, Alex; Gibb, Diana M; Walker, A Sarah; Maitland, Kathryn
- Abstract
<bold>Background: </bold>Severe anemia (SA, hemoglobin <6 g/dl) is a leading cause of pediatric hospital admission in Africa, with significant in-hospital mortality. The underlying etiology is often infectious, but specific pathogens are rarely identified. Guidelines developed to encourage rational blood use recommend a standard volume of whole blood (20 ml/kg) for transfusion, but this is commonly associated with a frequent need for repeat transfusion and poor outcome. Evidence is lacking on what hemoglobin threshold criteria for intervention and volume are associated with the optimal survival outcomes.<bold>Methods: </bold>We evaluated the safety and efficacy of a higher volume of whole blood (30 ml/kg; Tx30: n = 78) against the standard volume (20 ml/kg; Tx20: n = 82) in Ugandan children (median age 36 months (interquartile range (IQR) 13 to 53)) for 24-hour anemia correction (hemoglobin >6 g/dl: primary outcome) and 28-day survival.<bold>Results: </bold>Median admission hemoglobin was 4.2 g/dl (IQR 3.1 to 4.9). Initial volume received followed the randomization strategy in 155 (97%) patients. By 24-hours, 70 (90%) children in the Tx30 arm had corrected SA compared to 61 (74%) in the Tx20 arm; cause-specific hazard ratio = 1.54 (95% confidence interval 1.09 to 2.18, P = 0.01). From admission to day 28 there was a greater hemoglobin increase from enrollment in Tx30 (global P <0.0001). Serious adverse events included one non-fatal allergic reaction and one death in the Tx30 arm. There were six deaths in the Tx20 arm (P = 0.12); three deaths were adjudicated as possibly related to transfusion, but none secondary to volume overload.<bold>Conclusion: </bold>A higher initial transfusion volume prescribed at hospital admission was safe and resulted in an accelerated hematological recovery in Ugandan children with SA. Future testing in a large, pragmatic clinical trial to establish the effect on short and longer-term survival is warranted.<bold>Trial Registration: </bold>ClinicalTrials.Gov identifier: NCT01461590 registered 26 October 2011.
- Publication
BMC Medicine, 2014, Vol 12, Issue 1, p67
- ISSN
1741-7015
- Publication type
journal article
- DOI
10.1186/1741-7015-12-67